# SB-715992 in Treating Patients With Metastatic or Recurrent Malignant Melanoma

> **NCT00095953** · PHASE2 · COMPLETED · sponsor: **NCIC Clinical Trials Group** · enrollment: 17 (actual)

## Conditions studied

- Melanoma (Skin)

## Interventions

- **DRUG:** ispinesib

## Key facts

- **NCT ID:** NCT00095953
- **Lead sponsor:** NCIC Clinical Trials Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-11
- **Primary completion:** 2006-09
- **Final completion:** 2008-09
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2013-05-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00095953

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00095953, "SB-715992 in Treating Patients With Metastatic or Recurrent Malignant Melanoma". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00095953. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*